Artoss, Inc.

10/07/2025

Dr. Schneier discusses the success he is having using NanoBone in his spinal surgeries.

04/14/2025

02/24/2025

Artoss thanks Lyle Young, M.D. of Sonoran Spine for sharing this thought-provoking case “Diffuse idiopathic skeletal hyperostosis (DISH) treated with multilevel posterior spinal fusion of the thoracic-lumbar junction and placement of nanocrystalline hydroxyapatite (NanoBone® Bone Graft)”. Dr. Young was confident in using NanoBone in this patient despite the presence of abnormal calcification/bone formation (hyperostosis) of the soft tissues surrounding the joints of the spine. Fortunately, the patient achieved a solid fusion and a good clinical outcome.

This case has been excerpted from the Artoss Prospective Spine Registry Outcomes (ASTRO) post-market clinical registry study. This multicenter prospective patient registry was developed with the aim of documenting how orthopaedic and neurosurgeons are utilizing the NanoBone products along with relevant patient outcomes. Enrollment and patient follow-up is now complete. Artoss looks forward to sharing and publishing the results of this study.

10/07/2024

See the results of our post-market clinical registry using NanoBone® Bone Graft in foot and ankle surgery as published in Podiatry Today. Despite the presence of ample co-morbidities in this patient population, treatment with NanoBone resulted in statistically significant improvements in pain relief and function. 107 of 108 patients achieved bony fusion, a rate of 99.1%. Physical activity levels increased and use of pain medication decreased at six months post-surgery.

https://www.hmpgloballearningnetwork.com/site/podiatry/impact-nanocrystalline-hydroxyapatite-bone-graft-substitute-lower-extremity-osseous

09/26/2024

As the exclusive distributor of NanoBone® Bone Graft in North America, we are excited to be back at NASS 2024 here in Chicago. If you haven’t already, please stop by and see us at Booth #2327

09/11/2024

Artoss, Inc. looks forward to seeing the spine care community at the upcoming North American Spine Society (NASS) Annual Meeting from September 25-28, 2004 at McCormick Place West in Chicago, IL. We’ll be exhibiting the NanoBone® Bone Graft Substitute line of products at Booth 2327. Stop by and learn how NanoBone provides consistent, predictable outcomes in a great handling, ready to use format.

09/06/2024

See more outstanding clinical results using NanoBone® Bone Graft in posterolateral spinal fusion at the North American Spine Society (NASS) Annual Meeting from September 25-28, 2004 at McCormick Place West in Chicago, IL. Stop by Booth 2327 to learn more about how NanoBone provides consistent, predictable outcomes in a great handling, ready to use format.

06/21/2024

NanoBone requires no prep
NanoBone requires no tissue tracking
NanoBone has multiple delivery options
NanoBone stays where you put it (see video)
NanoBone has 2 standalone indications
NanoBone has patented science
NanoBone has been used in over 100,000 cases
Why wouldn’t you choose NanoBone as your bone graft?

06/18/2024

We are pleased to report that the Third Circuit Court of Appeals has affirmed the judgment in favor of Artoss Inc. in its litigation with Biocomposites GmbH (formerly Artoss GmbH) the manufacturer of NanoBone® Bone Graft Products.

06/11/2024

As trauma season is upon us, the coordination of NanoBone’s potency as a standalone bone graft and hardware would be an excellent 1-2 punch in returning the patient back to their prior quality of life. NanoBone’s mechanism of action in coordination with the body’s ability to remodel immature bone leads to predictable, effective regeneration of bone and ultimately off-weighting the rigid fixation no matter the area of the anatomy.

Please contact us at Artoss Inc with questions or needs.

06/04/2024

NanoBone is indicated for use as a standalone bone graft substitute by the FDA, utilizing patented nanotechnology. NanoBone's ability to stay where you put it, due to its superior handling properties, comes 2nd only to the efficacy & predictability of the FDA stand alone indication. Please message us for further information.